Literature DB >> 26004493

Mechanisms and therapeutic potential of microRNAs in hypertension.

Lijun Shi1, Jingwen Liao2, Bailin Liu2, Fanxing Zeng2, Lubo Zhang3.   

Abstract

Hypertension is the major risk factor for the development of stroke, coronary artery disease, heart failure and renal disease. The underlying cellular and molecular mechanisms of hypertension are complex and remain largely elusive. MicroRNAs (miRNAs) are short, noncoding RNA fragments of 22-26 nucleotides and regulate protein expression post-transcriptionally by targeting the 3'-untranslated region of mRNA. A growing body of recent research indicates that miRNAs are important in the pathogenesis of arterial hypertension. Herein, we summarize the current knowledge regarding the mechanisms of miRNAs in cardiovascular remodeling, focusing specifically on hypertension. We also review recent progress of the miRNA-based therapeutics including pharmacological and nonpharmacological therapies (such as exercise training) and their potential applications in the management of hypertension.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26004493      PMCID: PMC4609581          DOI: 10.1016/j.drudis.2015.05.007

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  196 in total

Review 1.  Getting to the root of miRNA-mediated gene silencing.

Authors:  Ana Eulalio; Eric Huntzinger; Elisa Izaurralde
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

2.  miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies.

Authors:  Deug-Chan Lee; Roberto Romero; Jung-Sun Kim; Adi L Tarca; Daniel Montenegro; Beth L Pineles; Ernest Kim; JoonHo Lee; Sun Young Kim; Sorin Draghici; Pooja Mittal; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Sonia S Hassan; Chong Jai Kim
Journal:  Am J Pathol       Date:  2011-08       Impact factor: 4.307

3.  Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium.

Authors:  Yun Fang; Peter F Davies
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-19       Impact factor: 8.311

4.  HIF-1 alpha-induced up-regulation of miR-9 contributes to phenotypic modulation in pulmonary artery smooth muscle cells during hypoxia.

Authors:  Fabo Shan; Junxia Li; Qing-Yuan Huang
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

5.  Multifaceted roles of miR-1s in repressing the fetal gene program in the heart.

Authors:  Yusheng Wei; Siwu Peng; Meng Wu; Ravi Sachidanandam; Zhidong Tu; Shihong Zhang; Christine Falce; Eric A Sobie; Djamel Lebeche; Yong Zhao
Journal:  Cell Res       Date:  2014-01-31       Impact factor: 25.617

6.  A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Authors:  Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2012-06-19       Impact factor: 17.367

7.  MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4.

Authors:  Changqing Xie; Huarong Huang; Xuan Sun; Yanhong Guo; Milton Hamblin; Raquel P Ritchie; Minerva T Garcia-Barrio; Jifeng Zhang; Y Eugene Chen
Journal:  Stem Cells Dev       Date:  2010-10-18       Impact factor: 3.272

8.  Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies.

Authors:  Xiao-ming Zhu; Tao Han; Ian L Sargent; Guo-wu Yin; Yuan-qing Yao
Journal:  Am J Obstet Gynecol       Date:  2009-03-14       Impact factor: 8.661

9.  Differentially expressed plasma microRNAs and the potential regulatory function of Let-7b in chronic thromboembolic pulmonary hypertension.

Authors:  Lijuan Guo; Yuanhua Yang; Jie Liu; Lei Wang; Jifeng Li; Ying Wang; Yan Liu; Song Gu; Huili Gan; Jun Cai; Jason X-J Yuan; Jun Wang; Chen Wang
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

10.  MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension.

Authors:  Ryan S Friese; Angelina E Altshuler; Kuixing Zhang; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Martin L Jirout; Rany M Salem; Jiaur R Gayen; Nitish R Mahapatra; Nilima Biswas; Mo Cale; Sucheta M Vaingankar; Hyung-Suk Kim; Maïté Courel; Laurent Taupenot; Michael G Ziegler; Nicholas J Schork; Michal Pravenec; Sushil K Mahata; Geert W Schmid-Schönbein; Daniel T O'Connor
Journal:  Hum Mol Genet       Date:  2013-05-13       Impact factor: 6.150

View more
  21 in total

1.  MicroRNAs are Necessary for BMP-7-induced Dendritic Growth in Cultured Rat Sympathetic Neurons.

Authors:  Kristina Pravoverov; Katherine Whiting; Slesha Thapa; Trevor Bushong; Karen Trang; Pamela J Lein; Vidya Chandrasekaran
Journal:  Cell Mol Neurobiol       Date:  2019-05-18       Impact factor: 5.046

Review 2.  Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases.

Authors:  Sébastien Bonnet; Olivier Boucherat; Roxane Paulin; Danchen Wu; Charles C T Hindmarch; Stephen L Archer; Rui Song; Joseph B Moore; Steeve Provencher; Lubo Zhang; Shizuka Uchida
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-04       Impact factor: 4.249

3.  Epigenetic regulation of L-type voltage-gated Ca2+ channels in mesenteric arteries of aging hypertensive rats.

Authors:  Jingwen Liao; Yanyan Zhang; Fang Ye; Lin Zhang; Yu Chen; Fanxing Zeng; Lijun Shi
Journal:  Hypertens Res       Date:  2016-11-24       Impact factor: 3.872

Review 4.  Animal Models of Hypertension: A Scientific Statement From the American Heart Association.

Authors:  Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

5.  Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess.

Authors:  Alejandra Tapia-Castillo; Cristian A Carvajal; Jorge A Pérez; Carlos E Fardella
Journal:  Endocrine       Date:  2022-06-08       Impact factor: 3.925

6.  Acarbose attenuates migration/proliferation via targeting microRNA-143 in vascular smooth muscle cells under diabetic conditions.

Authors:  Wei-Yuan Chuang; Meng-Hsun Yu; Tsung-Yuan Yang; Kuei-Chuan Chan; Chau-Jong Wang
Journal:  J Food Drug Anal       Date:  2020-09-15       Impact factor: 6.157

7.  Association of MicroRNAs With Risk of Stroke: A Meta-Analysis.

Authors:  Yidong Deng; Peijian Huang; Fan Zhang; Tao Chen
Journal:  Front Neurol       Date:  2022-05-19       Impact factor: 4.086

Review 8.  Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart.

Authors:  Csaba Csonka; Márta Sárközy; Márton Pipicz; László Dux; Tamás Csont
Journal:  Oxid Med Cell Longev       Date:  2015-12-14       Impact factor: 6.543

9.  Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.

Authors:  Giuseppe Mandraffino; Caterina Oriana Aragona; Valentina Cairo; Michele Scuruchi; Alberto Lo Gullo; Angela D'Ascola; Angela Alibrandi; Saverio Loddo; Sebastiano Quartuccio; Carmela Morace; Enricomaria Mormina; Giorgio Basile; Antonino Saitta; Egidio Imbalzano
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

10.  The expression of miR-211-5p in atherosclerosis and its influence on diagnosis and prognosis.

Authors:  Yanxia Zhang; Huiyun Wang; Yu Xia
Journal:  BMC Cardiovasc Disord       Date:  2021-08-02       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.